These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27239255)

  • 1. A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.
    Xia F; George SL; Wang X
    Stat Biopharm Res; 2016; 8(1):12-21. PubMed ID: 27239255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical review of oncology clinical trial design under non-proportional hazards.
    Ananthakrishnan R; Green S; Previtali A; Liu R; Li D; LaValley M
    Crit Rev Oncol Hematol; 2021 Jun; 162():103350. PubMed ID: 33989767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA; Wetmore JB; Mayo MS
    Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconsideration of sample size and power calculation for overall survival in cancer clinical trials.
    Jung I; Ko HJ; Rha SY; Nam CM
    Contemp Clin Trials Commun; 2018 Dec; 12():90-91. PubMed ID: 30302417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
    Fojo T; Amiri-Kordestani L; Bates SE
    J Natl Cancer Inst; 2011 Dec; 103(23):1738-40. PubMed ID: 22045362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
    Kümmel S; Jackisch C; Müller V; Schneeweiss A; Klawitter S; Lux MP
    Cancer Manag Res; 2018; 10():5423-5431. PubMed ID: 30519090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size calculation for the combination test under nonproportional hazards.
    Cheng H; He J
    Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
    Phadnis MA; Mayo MS
    Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2013 Dec; 13():152. PubMed ID: 24314264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study.
    Zhang L; Ko CW; Tang S; Sridhara R
    Ther Innov Regul Sci; 2013 Jan; 47(1):95-100. PubMed ID: 30227487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-state network meta-analysis of progression and survival data.
    Jansen JP; Incerti D; Trikalinos TA
    Stat Med; 2023 Aug; 42(19):3371-3391. PubMed ID: 37300446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.
    Kim HT; Gray R
    Clin Trials; 2012 Apr; 9(2):155-63. PubMed ID: 22353928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.
    Ishak KJ; Caro JJ; Drayson MT; Dimopoulos M; Weber D; Augustson B; Child JA; Knight R; Iqbal G; Dunn J; Shearer A; Morgan G
    Value Health; 2011; 14(5):672-8. PubMed ID: 21839405
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.